CAR-T cell therapy for gastric cancer:advances and challenges from target discovery to clinical translation
10.12354/j.issn.1000-8179.2025.20251059
- VernacularTitle:CAR-T细胞治疗胃癌:从靶点探索到临床转化的突破与挑战
- Author:
Liu LIAN
1
;
Tao MIN
;
Li JIARUI
;
Liu CHANG
;
Qi CHANGSONG
;
Shen LIN
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所消化肿瘤内科,恶性肿瘤发病机制及转化研究教育部重点实验室,实体瘤细胞与基因治疗北京市重点实验室(北京市 100142)
- Publication Type:Journal Article
- Keywords:
CAR-T cell therapy;
gastric cancer;
target;
solid tumor
- From:
Chinese Journal of Clinical Oncology
2025;52(16):820-825
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer is a malignant tumor with high prevalence worldwide and limited therapeutic options.Chimeric antigen receptor T-cell(CAR-T)therapy has emerged as a promising approach for gastric cancer treatment;however,its application faces substantial challenges.This review provides comprehensive summary of the recent advances in CAR-T cell therapy for gastric cancer,systematic analysis of critical break throughs and core challenges from target discovery to clinical translation,and outlining of future perspectives.We describe the criter-ia for ideal target selection and highlight the current research landscape of major targets,including CLDN18.2 that demonstrated efficacy,and targets facing distinct challenges,including HER-2,CEA,EpCAM,and MUC1.This review also finely dissects three central barriers restrict-ing CAR-T cell efficacy,and discusses corresponding countermeasures:overcoming the immunosuppressive tumor microenvironment through strategies such as local delivery,armored CAR-T cells,and combination therapies;engineering approaches including affinity modula-tion and logic-gate designs to mitigate on-target/off-tumor toxicity;and optimization of manufacturing processes and reduction of costs via early leukapheresis,rapid production platforms,and universal CAR-T cell strategies.Future multidimensional,integrative,and innovative strategies are pivotal for achieving comprehensive break throughs in CAR-T cell therapy for solid tumors.